Early local therapy in combination with PD-1/PD-L1 inhibitors in oligometastatic non-small cell lung cancer: results from a prospective multicenter observational study
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04016-0 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Jie Gao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Fudan University Shanghai Cancer Center, No.270, Dong'an Road, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immune Checkpoint Inhibitors, B7-H1 Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Chinese Society of Clinical Oncology, the Shanghai Science and Technology Committee.
Abstract (Originalsprache)
PURPOSE: Appropriate local therapy may provide survival benefits in oligometastatic non-small cell lung cancer (NSCLC) patients receiving chemotherapy or targeted therapy. However, its roles in immunotherapy-treated patients have not been fully understood. METHODS: PD-1/PD-L1 inhibitor-treated metastatic NSCLC patients were enrolled in a prospective multi-center observational study (NCT04766515) from September 2020 to March 2023. Those without driver mutations, with measurable disease and harboring oligometastatic disease were included. Progression-free survival (PFS) and overall survival (OS) were compared between those with or without early local therapy (eLT). Moreover, eLT performed within or after 1 month of the initiation of PD-1/PD-L1 inhibitors was defined as concurrent- or sequential-LT, respectively. While, eLT targeting partial or all of the tumor lesions, was described as partial- or all-LT, respectively. RESULTS: Among the 180 patients identified, eLT was performed in 44, including concurrent-LT in 25 and all-LT in 19, respectively. With a median follow-up of 19.40 months, progressive disease occurred in 95 of the 136 patients without eLT. Compared to those without eLT, patients receiving eLT had significantly longer PFS (HR = 0.40, 95% CI 0.27-0.59, p < 0.0001) and OS (HR = 0.43, 95% CI 0.24-0.76, p = 0.02). Moreover, eLT was associated with improved survival after Cox analyses and propensity score matching. Meanwhile, sequential-LT, as well as all-LT, was associated with longer OS, when compared with concurrent-LT or partial-LT, respectively. CONCLUSIONS: Early local therapy, especially those performed after effective systemic therapy and targeting all tumor lesions, may prolong patient's survival in PD-1/PD-L1 inhibitor-treated oligometastatic NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, No.270, Dong'an Road, Shanghai, 200032, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
- Shanghai Clinical Research Center for Radiation Oncology, Shanghai, China.
- Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
- Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Oncology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Förderung
- the Chinese Society of Clinical Oncology
- the Shanghai Science and Technology Committee
Zitieren
APA
Gao, J., Lan, A., Yang, X., Chu, L., Chu, X., Zhou, Y., Chen, H., Yu, S., Pang, Y., Hu, J., Chu, Q., Ni, J., & Zhu, Z. (2025). Early local therapy in combination with PD-1/PD-L1 inhibitors in oligometastatic non-small cell lung cancer: results from a prospective multicenter observational study. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04016-0
Vancouver
Gao J, Lan A, Yang X, Chu L, Chu X, Zhou Y, et al. Early local therapy in combination with PD-1/PD-L1 inhibitors in oligometastatic non-small cell lung cancer: results from a prospective multicenter observational study. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04016-0
BibTeX
@article{Gao2025,
author = {Gao, Jie and Lan, Aihua and Yang, Xi and Chu, Li and Chu, Xiao and Zhou, Yue and Chen, Hongru and Yu, Silai and Pang, Yechun and Hu, Jie and Chu, Qian and Ni, Jianjiao and Zhu, Zhengfei},
title = {Early local therapy in combination with PD-1/PD-L1 inhibitors in oligometastatic non-small cell lung cancer: results from a prospective multicenter observational study},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04016-0}
}
EUVIMED